(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 April 2009 (30.04.2009)

PCT

(10) International Publication Number
WO 2009/055343 A3

(51) International Patent Classification:
C12P 21/08 (2006.01)

(21) International Application Number:
PCT/US2008/080531

(22) International Filing Date:
20 October 2008 (20.10.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/981,808 22 October 2007 (22.10.2007) US
61/046,370 18 April 2008 (18.04.2008) US

(71) Applicants *(for all designated States except US)*: **SCHERING CORPORATION** [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). **XOMA TECHNOLOGY LTD.**; Clarendon House, 2 Church Street, Hamilton, HM11 (BM).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **RAMACHANDRA, Sumant** [US/US]; 16 Dorothy Lane, East Brunswick, New Jersey 08850 (US). **BISHOP, Walter, Robert** [US/US]; 17 Hopper Avenue, Pompton Plains, New Jersey 07444 (US). **MASAT, Linda** [IT/US]; 2728 San Antonio Drive, Walnut Creek, California 94598 (US). **HUANG, Chao, Bai** [US/US]; 345 Accolade Drive, San Leandro, California 94577 (US). **TAKEUCHI, Toshihiko** [US/US]; 6529 Ascot Drive, Oakland, California 94611 (US). **KANTAK, Seema** [US/US]; 1230 Sheila Lane, Pacifica, California 94044 (US). **HUANG, Chin-Yi** [US/US]; 3310 Willet Place, Fremont, CA 94555 (US).

(74) Agent: **MORRIS, Patrick, D.**; Perkins Coie LLP, P.O. Box 1208, Seattle, Washington 98111-1208 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

(88) Date of publication of the international search report:
24 September 2009

(54) Title: FULLY HUMAN ANTI-VEGF ANTIBODIES AND METHODS OF USING

(57) Abstract: Disclosed herein are fully human antibodies and antigen-binding fragments thereof that specifically bind human VEGF and inhibit VEGF binding to VEGF-R1 and VEGF-R2, and therefore inhibit VEGF signaling. The antibodies and antigen-binding fragments disclosed herein may be used, for example, to treat angiogenesis and conditions associated with angiogenesis both *in vivo* and *in vitro*.

WO 2009/055343 A3